Sucampo Appoints John H. Johnson to Board of Directors
December 15 2014 - 6:45AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced the appointment of John
H. Johnson, founder, Plum Brook Advisors, to its board of directors
(Board).
"We are pleased to welcome John to our Board during Sucampo's
continued evolution," said Peter Greenleaf, chief executive officer
of Sucampo. "As a recognized leader in the biopharmaceutical
industry who has tremendous experience in building and growing
science-focused companies, John will be instrumental as we continue
to execute on our strategic objectives, accelerate the development
of our pipeline, and diversify our science."
Mr. Johnson brings more than 30 years of leadership experience
in the pharmaceutical and biotechnology industry to Sucampo. He has
held executive management roles at leading global corporations,
including Johnson & Johnson, Eli Lilly & Company, ImClone
and Pfizer, Inc. He recently served as a member of the board of
directors of Pharmaceutical Research and Manufacturers of America
(PhRMA) and as a member of the Health Section Governing Board of
Biotechnology Industry Organization (BIO). He also served as
chairman, president and chief executive officer of Dendreon
Corporation and as chief executive officer and Board member of
Savient Pharmaceuticals, Inc. Prior to these roles, Mr. Johnson
served as president of Eli Lilly & Company's Oncology Unit
following its 2008 acquisition of Imclone Systems, Inc., where he
served as chief executive officer and Board member. Before joining
Imclone, he held various executive roles of increasing
responsibility, including Company Group Chairman of
Biopharmaceuticals at Johnson & Johnson, where he was
responsible for the Johnson & Johnson Biotechnology, Immunology
and Oncology commercial businesses. Earlier in his career, Mr.
Johnson held multiple executive positions at Parkstone Medical
Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp. and
Pfizer, Inc. Mr. Johnson served as the chairman of Tranzyme Pharma,
Inc. and as a member of the board of BioNJ. Mr. Johnson currently
serves as a member of the board of directors of Cempra
Pharmaceuticals, Inc., Histogenics and Portola Pharmaceuticals.
"I am excited about the opportunity to join Sucampo's board of
directors and leadership team," said John H. Johnson. "I look
forward to contributing to Sucampo's future growth and success
developing and diversifying its pipeline and its delivery to
patients in need and healthcare providers around the world."
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and
commercialization of medicines that meet major unmet medical needs
of patients worldwide. Sucampo has two marketed products – AMITIZA®
and RESCULA® – and a pipeline of drug candidates in clinical
development. A global company, Sucampo is headquartered in
Bethesda, Maryland, and has operations in Japan, Switzerland and
the United Kingdom. For more information, please visit
www.sucampo.com.
The Sucampo logo is the registered trademark and the tagline,
The Science of Innovation, is a pending trademark of Sucampo AG.
AMITIZA is a registered trademark of Sucampo AG. RESCULA is a
registered trademark of R-Tech Ueno, Ltd, and has been licensed to
Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals).
Twitter LinkedIn
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, future financial
and operating results, and other statements that are not historical
facts. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and
health care legislation; Sucampo's ability to accurately predict
future market conditions; dependence on the effectiveness of
Sucampo's patents and other protections for innovative products;
the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or
regulatory actions. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected.
Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in
Sucampo's most recent Forms 8-K and 10-K, which Sucampo
incorporates by reference.
CONTACT: Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations
and Corporate Communications
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024